

Date: January 17, 2017

To  Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUOPHARMA</b>	To  The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
---	--

Dear Sirs,

**Sub: Transcript of Analyst / Investor Call**

Please refer to our letter dated January 7, 2017 informing that an Analyst / Investor call on acquisition of 100% shareholding in Generis Farmacêutica S.A., a Portuguese pharmaceutical company engaged in the manufacture and marketing of pharmaceutical products in Portugal by our wholly owned step-down subsidiary, Agile Pharma B.V., Netherlands was scheduled on at 6.00 p.m (IST) on Monday 9<sup>th</sup> January, 2017. The Analyst / Investor call took place at 6.00 p.m (IST) on Monday 9<sup>th</sup> January, 2017.

We would like to inform you that the Transcript of the Analyst / Investor call on 9<sup>th</sup> January, 2017 has been uploaded on the website of our Company and is available in the following web link.

<http://www.aurobindo.com/investor-relations/investors/investor-presentation>

Please take the information on record.

Thanking you,

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**

*B. Adi Reddy*  
**B. ADI REDDY**  
Company Secretary

